This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209)	<p>Cell culture and mouse studies identified DC-SIGN-binding mannodendrimers that could help treat inflammatory diseases. Mannodendrimers are comprised of poly(phosphorhydrazone) dendrimers grafted with mannose units of varying length. In lipopolysaccharide (LPS)-stimulated human dendritic cells, the mannodendrimers selectively bound to DC-SIGN and decreased tumor necrosis factor-α (TNF-α) secretion compared with vehicle. In a mouse model for LPS-induced acute lung inflammation, a mannodendrimer decreased lung neutrophil recruitment compared with vehicle. Next steps could include testing the mannodendrimer in additional mouse models for inflammatory diseases.</p> <p>SciBX 6(22); doi:10.1038/scibx.2013.549 Published online June 6, 2013</p>	Patent and licensing status unavailable	<p>Blattes, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 13, 2013; doi:10.1073/pnas.1221708110</p> <p>Contact: Germain Puzo, Institute of Pharmacology and Structural Biology, Toulouse, France e-mail: germain.puzo@ipbs.fr</p>